INFLUENCE OF BRAIN-SPECIFIC PROTEIN S-100 AND ENDOTHELIAL NO-SYNTHASE ANTIBODIES-CONTAINING DRUG ON DEGREE OF ANXIOUS-DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC STROKE IN EARLY REHABILITATION PERIOD
O S Golovina , P P Kalinsky , E V Eliseeva , D P Kalinsky
Perm Medical Journal ›› 2017, Vol. 34 ›› Issue (5) : 28 -34.
INFLUENCE OF BRAIN-SPECIFIC PROTEIN S-100 AND ENDOTHELIAL NO-SYNTHASE ANTIBODIES-CONTAINING DRUG ON DEGREE OF ANXIOUS-DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC STROKE IN EARLY REHABILITATION PERIOD
Aim. To estimate the dynamics of asthenic and anxious-depressive disorders in the early rehabilitation period of ischemic stroke against the background of taking a drug, containing antibodies to brain-specific protein S-100 and endothelial NO-synthase. Materials and methods. Sixty five patients (45 men and 20 women) with a mean age of 63.5 ± 5.3 years were examined in the early rehabilitation period of ischemic stroke. Neuropsychological examination inclu-ded the following tests: subjective multidimentional fatigue inventory (MFI-20), hospital anxiety and depression scale (HADS), National Institute of Health Stroke Scale (NIHSS). Results. After a course of taking a drug, containing antibodies to brain-specific protein S-100 and endothelial NO-synthase, manifestation of asthenia reduced in the main group by 35.48 %, p < 0.05, in the group of compari-son - by 9.57 %; anxious-depressive symptomatology decreased by 26.91 %, p < 0.05 and 5.16 %, respectively. Conclusions. Against the background of taking a brain-specific protein S-100 and endothelial NO-synthase antibodies-containing drug in the dose of 0.036 g, patients of the main group demonstrated faster regression of asthenic, anxious-depressive symptomatology and reduction of neurological deficiency manifestation.
Ischemic stroke / early rehabilitation period / asthenic disorders / anxious-depressive symptomatology / antibodies to brain-specific protein S-100 and endothelial NO-synthase
| [1] |
Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина 2001; 328. |
| [2] |
Кулеш А.А., Шестаков В.В. Хронобиологические показатели, когнитивный, эмоциональный статус и качество сна в остром периоде инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова 2013; 113 (7): 24-28. |
| [3] |
Федин А.И. Современные аспекты нейропротекции и нейропластичности: от теории к практике. Инновационные подходы к нейропротекции: материалы науч.-практ. конф. М. 2012. |
| [4] |
Хейфец И.А., Воронина Т.А., Молодавкин Г.М., Дугина Ю.Л. Экспериментальное изучение анксиолитического антидепрессивного действия препарата диваза. Материалы VIII Междунар. междисцип. конгр. «Нейронаука для медицины и психологии». Судак 2012. |
| [5] |
Щукин И.А., Лебедева А.В., Чубыкин В.И. Астения у пациентов с хроническими неврологическими заболеваниями. Клиницист 2013; 2: 64-71. |
| [6] |
Desmond D.W., Moroney J.T., Paik M.C. Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000; 54: 1124-1131. |
| [7] |
Glader E.L., Stegmayr B., Asplund K. Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke 2002; 33 (5): 1327-1333. |
| [8] |
Oken B.S., Kishiyama S., Zajdel D. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004; 62 (11): 2058-2064. |
| [9] |
Schon E.A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest 2003; 111 (3): 303-312. |
| [10] |
Winward C., Sackley C., Metha Z., Rothwell P.M. A population-based study of the prevalence of fatigue after transient ischemic attack and minor stroke. Stroke 2009; 40 (3): 757-761. |
| [11] |
Williams L.S., Ghose S.S., Swindle R.W. Depression and other mental health diagnoses increase mortality risk after ischemic stroke. American Journal of Psychiatry 2004; 161 (6): 1090-1095. |
Golovina O.S., Kalinsky P.P., Eliseeva E.V., Kalinsky D.P.
/
| 〈 |
|
〉 |
PDF
